MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug development company, has announced the expansion of its Phase I clinical trial for MVT-5873 to include the HonorHealth Research Institute in Scottsdale, Arizona. This trial is focused on assessing the safety, tolerability, and pharmacokinetics of MVT-5873, a fully human therapeutic antibody, in patients with metastatic pancreatic cancer. The trial is divided into two parts: the first part involves a traditional dose escalation regimen to determine the recommended phase 2 dose (RP2D), while the second part aims to establish the safety and RP2D of MVT-5873 when used alongside standard chemotherapy.
Dr. Erkut Borazanci, the lead investigator at HonorHealth Research Institute, highlighted the institute's involvement in treating advanced pancreatic cancer with a combination of nab-paclitaxel, gemcitabine, nanoliposomal irinotecan, and 5-Fluorouracil. He expressed enthusiasm about the partnership with MabVax Therapeutics, emphasizing the potential of MVT-5873 as a new therapeutic option for patients with advanced pancreatic cancer.
David Hansen, President and CEO of MabVax, expressed excitement about collaborating with HonorHealth Research Institute, noting its expertise in developing new therapeutic agents for pancreatic cancer. MVT-5873, discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine, has shown high specificity and affinity in preclinical research, demonstrating potent cancer cell killing capacity in animal models of pancreatic, colon, and small cell lung cancers.
This expansion of the Phase I trial represents a significant step forward in the search for effective treatments for pancreatic cancer, a disease with limited therapeutic options for patients with advanced stages. The collaboration between MabVax Therapeutics and HonorHealth Research Institute underscores the importance of combining scientific insights with clinical expertise to bring new hope to patients battling this challenging disease.
